A groundbreaking new approach to treatment is now available for individuals battling serious illnesses. The U.S. Food and Drug Administration (FDA) has recently given the green light to the initial oral medication specifically designed for psoriasis.
Simultaneously, a similar application has been submitted to the European Medicines Agency (EMA) for consideration. Johnson & Johnson, a prominent pharmaceutical firm, has announced the FDA’s approval of Icotyde, a novel drug. This oral medication functions as an inhibitor of IL-23, targeting receptors involved in the condition.
It’s intended for the management of moderate to severe plaque psoriasis. This innovative treatment holds the potential to provide significant relief to a large number of people affected by this persistent skin ailment. What exactly is psoriasis and what symptoms are associated with it?
Psoriasis is a chronic, autoimmune disease, often influenced by genetic factors. It’s characterized by skin conditions that resemble systemic diseases, presenting with various symptoms. The development of this first oral drug represents a major step forward in managing this challenging condition.
Topics: #oral #drug #first